Is your COUGH due to asthma?
Cough is one of the most common reasons why patients visit their primary care physician, and it can be one of the symptoms seen in asthma. In some individuals with asthma, cough is the only symptom.1,2
ARIDOL® (mannitol) is indicated for the assessment of bronchial hyperresponsiveness (BHR) in adult and pediatric patients 6 years of age or older who do not have clinically apparent asthma. BHR is a key clinical feature of respiratory conditions such as exercise-induced bronchoconstriction and asthma.5
The right diagnosis is critical
Bronchial challenge tests with Provocholine® (methacholine chloride) and Aridol® (mannitol) can help find the right diagnosis.
Learn more about bronchial challenge tests
(CRCE credits)
Connect with a Clinical Specialist to schedule your complimentary Education Session (CRCE credit options)
Please enter your name and email below.
Focused on every breath
At Methapharm Respiratory we take pride in working with healthcare practitioners to support the right diagnosis for patients exhibiting common respiratory symptoms such as cough, wheeze and shortness of breath. Asthma symptoms are shared across many respiratory conditions and misdiagnosis can easily occur, resulting in patients being placed on ineffective and unnecessary treatments and delaying treatment for the correct diagnosis.
Methapharm Respiratory supports clinicians in the diagnostic process with methacholine and mannitol challenge tests as objective measures of airway hyperresponsiveness.
We also offer training and education (CRCE) at no cost.
For more information, please contact Methapharm at
1-833-887-7686, send an email or visit
Provocholine® (methacholine chloride)
INDICATION: Provocholine is indicated for the diagnosis of bronchial airway hyperreactivity in adults and pediatric patients 5 years of age and older who do not have clinically apparent asthma.
WARNING: SEVEREÂ BRONCHOCONSTRICTION
WARNING: SEVERE BRONCHOCONSTRICTION Severe bronchoconstriction can result from Provocholine administration (including the lowest dose). The use of Provocholine is contraindicated in pediatric and adult patients with baseline FEV1 < 60% predicted or adults with FEV1 < 1.5 L. Because of the potential for severe bronchoconstriction, the use of Provocholine in patients with clinically apparent asthma or wheezing is not recommended. Emergency equipment and medication should be immediately available to treat acute respiratory distress. If severe bronchoconstriction occurs, reverse immediately with a rapid-acting inhaled bronchodilator agent (β-agonist). If baseline spirometry is not performed or is measured inaccurately, the initial FEV1 may be underestimated. In this situation, decreases in FEV1 may not be detected after administration of escalating Provocholine doses, which may result in administration of unnecessary higher doses and an increased risk for excessive bronchoconstriction [see Warnings and Precautions – Section 5.1 of the Prescribing Information].
Aridol® (mannitol inhalation powder)
INDICATION: ARIDOL is a sugar alcohol indicated for the assessment of bronchial hyperresponsiveness in adult and pediatric patients 6 years of age or older who do not have clinically apparent asthma.
Mannitol, the active ingredient in ARIDOL, acts as a bronchoconstrictor and may cause severe bronchospasm. Bronchial challenge testing with ARIDOL is for diagnostic purposes only. Bronchial challenge testing with ARIDOL should only be conducted by trained professionals under the supervision of a physician familiar with all aspects of the bronchial challenge test and the management of acute bronchospasm. Medications (such as short-acting inhaled beta-agonist) and equipment to treat severe bronchospasm must be present in the testing area. If severe bronchospasm occurs, it should be treated immediately by administration of a short acting inhaled beta-agonist. Because of the potential for severe bronchoconstriction, the bronchial challenge testing with ARIDOL should not be performed in any patient with clinically apparent asthma or very low baseline pulmonary function tests (e.g., FEV1<1-1.5 liters or <70% of the predicted values) [see Warnings and Precautions (5.1) of the Prescribing Information].
References
- Niimi, A. Cough and Asthma. Curr Respir Med Rev (2011) 7(1), 47-54(8).
- Rybka-Fraczek, A et al. Does bronchial hyperresponsiveness predict a diagnosis of cough variant asthma in adults with chronic cough: a cohort study. Respir Res (2021) 22:252.
- Morice, AH et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. (2020) 55:1901136.
- Provocholine package insert, revised 11/2020.
- Aridol package insert, revised 08/2021.
Provocholine® is a registered trademark of Methapharm Inc. Aridol® is a registered trademark of Pharmaxis Ltd. 20 Rodborough Rd, Frenchs Forest NSW 208, Australia.
Aridol is distributed by Methapharm in the United States. Copyright © Methapharm Inc. 2023. All rights reserved.